Download our new White Paper now: Environmental Beneﬁts of NorthStar Medical Radioisotopes’ Non–Uranium-Based Production Method for Molybdenum-99/Technetium-99m
Our innovative products and technologies define a new era in current and future diagnostic and therapeutic radiopharmaceuticals.
We lead the way in producing stable, reliable, domestically-sourced, environmentally-friendly radioisotope supply to meet critical patient healthcare needs and advance clinical research.
Our people drive our solutions in advancing radioisotope technology to shape a better world.
We are a recognized, emerging global leader with a proven track record and strong vision for the future of radiopharmaceuticals. Our innovation-driven technology is transforming the landscape for medical radioisotope production and distribution around the world.
NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation SummitRead More >
NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)Read More >
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human TrialsRead More >
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)Read More >